A global diversified healthcare company and industry leader
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2013 sales of $15.3 billion and has approximately 61,500 employees.
A Career With a Higher Purpose
Baxter’s unique combination of expertise in medical devices, biotechnology and pharmaceuticals differentiates us from other companies in the healthcare industry, and makes us an attractive employer that offers a variety of possibilities. We hire a range of talented and driven people with diverse skill sets and backgrounds, from scientists and researchers to roles in manufacturing, engineering, law, marketing and sales, to name just a few.
2012 Sales-$6.2 Billion
Baxter is a leading manufacturer of recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and vaccines.
2012 Sales-$8.0 Billion
Baxter’s Medical Products business manufactures products used in the delivery of fluids and drugs to patients. These include intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, IV nutrition products, infusion pumps and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, Baxter's Medical Products business is a leader in Renal home-based therapies, such as peritoneal dialysis, and offers other products and services for people with end-stage kidney disease.
2012 Sales by Business
2012 Sales by Region
Regional Employee Breakdown
|United States|| |
|Latin America/Canada|| |
|Asia Pacific|| |
R&D Expenditures (in millions)
Because of our longstanding commitment to research and development, Baxter’s history is rich with medical firsts, from the first commercially manufactured intravenous (IV) solutions to the first portable kidney dialysis machine, plus many more. Baxter continually pursues breakthrough technologies through research facilities around the world, and our investments reflect that commitment.
One of Baxter’s competitive strengths is its diverse technological expertise and commitment to scientific innovation. The company’s unique combination of capabilities in medical devices, pharmaceuticals and biotechnology, including specialty biologics, sets it apart from other companies in the healthcare industry.
Core Technical Competencies
Each of Baxter’s six core technical competencies represents a specialized area of technical expertise and leadership that enables the company to develop and manufacture unique healthcare products.
• Biologics – Baxter’s leadership in plasma fractionation, the process of breaking down blood plasma into its component parts, is the foundation of many contemporary biologically derived therapies, including treatments for hemophilia and primary immunodeficiency. The company also has extensive expertise in recombinant protein production, using the proprietary plasma- and albumin- free (PAF) recombinant protein technology as a basis for current treatments as well as a number of others currently in development. Baxter also is involved in leading-edge research and development in recombinant therapeutics, vaccines and regenerative medicine.
• Drug Delivery – Baxter introduced the first commercially produced intravenous (IV) solutions, premixed in glass containers and shipped ready for use, and later introduced the world’s first flexible, plastic IV containers. Baxter was also the first company to partner with pharmaceutical firms to premix their drugs in IV solutions for safe and efficient delivery to patients. The company’s expertise includes formulating and packaging injectable drugs in vials and syringes, and advanced drug formulation technologies.
• Hardware and Software Development –Many of the therapies that Baxter has pioneered require the use of a device for the controlled delivery of fluids. The company offers unique capabilities in the design, development and integration of hardware and electronic systems and the software that controls them. Baxter also incorporates human factors (the manner in which a clinician or patient interacts with or uses a device) into the design of products.
• Medical Plastics – Baxter revolutionized blood collection with the first flexible plastic blood-collection container, which led to the first flexible plastic IV solution container for IV therapy. Soon thereafter Baxter introduced the MINI-BAG container systems for IV drugs, and the flexible plastic containers used in peritoneal dialysis, the first portable dialysis therapy.
• Solutions – Baxter applies its expertise in solutions to develop a variety of therapies, including parenteral nutrition and peritoneal dialysis. Therapeutic solutions such as these present a variety of scientific and technical challenges including stability, chemical degradation, compatibility of ingredients and precipitation. Baxter uses a variety of techniques to overcome these challenges and ensure quality, consistency and ease of use.
• Sterilization – Baxter has pioneered a range of sterilization platforms to meet the unique requirements and characteristics of its biopharmaceutical, IV and injectable pharmaceutical and medical device products. Baxter’s sterilization capabilities include systems for validation and assurance, and development of novel chemical and biological indicators and barrier technologies. Baxter’s technology is the only commercially available aseptic filling process for premixed drugs in flexible IV containers.
Advancing Baxter's R&D Activities
In 2011, Baxter’s R&D investment of $946 million reached a record level for the company.Baxter introduced a number of new products, expanded indications of existing products and advanced approximately 20 key R&D programs within late-stage clinical development, many of which have the potential to profoundly improve the treatment and delivery of care for chronic diseases like hemophilia, immune deficiencies, Alzheimer’s disease and end-stage kidney disease. To further enhance Baxter’s early-stage pipeline, the company established Baxter Ventures to invest in promising early-stage therapies and technologies in line with Baxter’s strategic direction.
Baxter’s enduring growth depends on a consistently innovative pipeline of new offerings that broaden the company’s portfolio of medically necessary products and therapies while reinforcing leadership in core therapeutic areas. Examples in 2011 include:
Meeting Unmet Needs: A focus of Baxter's R&D pipeline is on products and therapies that have the potential to satisfy unmet clinical needs by improving earlier diagnosis, prevention and treatment and providing new, unrecognized solutions.
- Baxter completed enrollment in the first pivotal Phase III clinical trial evaluating the use of GAMMAGARD LIQUID 10% (marketed as KIOVIG in Europe) for the treatment of mild to moderate Alzheimer¡¦s disease. The company has initiated a second, confirmatory Phase III trial.
- The company also initiated a global Phase III clinical trial to evaluate the safety and effectiveness of BAX 111, Baxter¡¦s investigational recombinant von Willebrand factor (rVWF), in the treatment of bleeding events in patients with type 3 and severe non-type 3 von Willebrand disease, the most common inherited bleeding disorder. BAX 111 is the first recombinant therapy in clinical development for von Willebrand disease.
- In January 2012, Baxter initiated a Phase I clinical trial of BAX 855, a longer-acting (PEGylated) factor VIII based on the full-length ADVATE molecule and plasma/ albumin-free manufacturing process.
- Multifocal motor neuropathy (MMN) is associated with a progressive, asymmetric limb weakness mostly affecting the upper limbs, which can lead to significant difficulty with simple manual tasks. Baxter received regulatory approval to market KIOVIG to treat MMN in Europe in 2011, and has submitted an application to add the indication to GAMMAGARD LIQUID in the United States.
- Baxter published Phase II data demonstrating that injections of a patient¡¦s own CD34+ adult stem cells into targeted sites in the heart have therapeutic benefits for patients suffering from chronic myocardial ischemia (CMI), one of the most severe forms of coronary artery disease, causing significant long-term damage to the heart muscle and disability to the patient. Based on this data, Baxter initiated a Phase III clinical trial in February 2012.
Improving Delivery of Care: Baxter is advancing several therapies that have the potential to profoundly impact the way care is delivered to patients through innovative uses of new and existing technologies.
- Baxter launched NEXTERONER (amiodarone HCl) Premixed Injection, the first and only ready-to-use premixed intravenous (IV) bag version of the antiarrhythmic agent amiodarone in the United States. In a premixed formulation, NEXTERONE does not require admixing (compounding), making it immediately available for use and also reducing the risk of medication errors associated with compounding, for example.
- The company expanded the indication of ARTISS [Fibrin Sealant (Human)] to include adhering tissue flaps during facial rhytidectomy surgery (face-lift). ARTISS is the only premixed, ready-to-use fibrin sealant specifically indicated for tissue adherence in facial rhytidectomy (face-lift) and burn surgeries.
- Baxter received FDA approval for a new prophylaxis indication for ADVATE recombinant factor VIII therapy for hemophilia A patients. The new indication offers some patients the option to reduce the frequency of prophylactic infusions to every third day.
- Later this year, Baxter is planning to start a global Phase 3 study to demonstrate the safety and efficacy of BAX817, a recombinant factor VIIa, in the treatment of acute bleeding episodes in hemophilia A or B patients with inhibitors.
- Enrollment has been completed in the Phase III clinical trial for BAX 326, a recombinant factor IX therapy for patients with hemophilia B.
- In Europe, Baxter introduced NUMETA as the first triple-chamber container nutrition system designed specifically for pre-term infants and children. This premix therapy addresses an important unmet medical need to support neonatal and pediatric patients' changing daily nutritional needs with ready-to-use IV nutrition.
Advancing Home Therapy: Baxter is improving technologies to make medicine more efficient and productive to benefit patients with an improved quality of life.
- Baxter continued research of a new home hemodialysis platform able to deliver high-dose (frequent or longer duration hemodialysis) to provide another option for patients seeking home dialysis for end-stage renal disease.
- Baxter submitted to United States, European and Canadian regulatory bodies for approval of HyQvia, Baxter¡¦s investigational immunoglobulin (IG) therapy administered subcutaneously and facilitated by recombinant human hyaluronidase for patients with primary immunodeficiencies. In addition to a reduced rate of serious bacterial infections, the Phase III study data suggest potentially useful attributes of HyQvia, such as the possibility for a three or four week dosing schedule with single-site, self-administered infusions.
- Baxter received FDA clearance for the company¡¦s new, next-generation automated peritoneal dialysis (APD) cycler and new HomeChoice SmartCare software for use in current HomeChoice APD machines.
Our global total compensation philosophy is to provide market-competitive pay while rewarding employees for individual and business performance. Our total compensation package includes base salary and may include incentive pay, such as cash bonuses and stock-based compensation. It also includes comprehensive benefits that vary by country, region and/or role, to help employees meet their healthcare, income-protection, financial, retirement and time-off needs.
Although the benefits we offer vary by country, most Baxter employees have the opportunity to share in the growth the company generates for shareholders through the Employee Stock Purchase Plan (ESPP).The ESPP allows Baxter employees to purchase Baxter common stock each month at a 15 percent discount (up to 15 percent of base pay and sales commissions) through convenient payroll deductions with no brokerage fees.
In addition, Baxter employees have access to a variety of health and wellness resources through BeWell@Baxter, the company’s global health and wellness program. These resources are designed to help employees focus on staying well through education and prevention, taking action to make healthy changes and dealing with chronic or acute conditions.
Career development at Baxter is based on our Leadership Expectations, the company’s integrated framework of Shared Values, Competencies and Personal Attributes that create a common understanding of what is expected of each employee. Our approach to career growth is also based on the company’s development philosophy, which emphasizes that professional evolution occurs through a combination of work experiences, feedback, relationships and training.
Our Development Philosophy
Our development philosophy underscores that the primary way employees develop is through work experiences. In fact, it is common to see 70 percent of an employee’s development achieved through these experiences. Feedback and building relationships are an important part of development as they help establish an employee’s professional network. Traditional training opportunities are also available to our employees.
We believe that development is:
Career Development Tools
We offer a variety of career development tools and resources that are designed to help employees assess their strengths and development needs, as well as their career interests and personal motivations. Employees are encouraged to use and refer to these resources on an ongoing basis.
In addition, employees have a variety of opportunities to grow and learn by taking advantage of online and in-classroom training programs. All employees have access to our global learning management system, which offers courses in multiple languages. The system contains more than 500 eLearning programs on subjects such as our focus on quality, Baxter processes and systems, company products, management and career development (including Harvard ManageMentor, a collection of online resources organized by specific leadership and management topics), PC skills, environment, health and safety, pharmacovigilance, project management and many more.
Through Management Essentials, a management-training curriculum, managers and supervisors receive additional training in a variety of areas including career and development planning, and coaching and feedback.
Also, experienced managers and directors receive training targeting their business acumen and their skills in motivating and developing others.
Having a diverse employee population (representing different ages, genders, sexual orientations, races, ethnicities or religions) is essential. Diversity alone, though, does not ensure an inclusive culture. An inclusive organization must have policies, programs, processes and systems in place that engender respect, value differences and enable all employees to work together effectively.
Baxter believes that an inclusive culture and a diverse workforce can drive innovation, create trusted partnerships with customers, suppliers and community partners and ultimately, contribute to the success and sustainability of the business.
These beliefs form the foundation of Baxter’s global inclusion strategy, which is directly linked to one of the company’s key shared values and leadership expectations—respect for individuals and the diverse contributions of all.
Baxter’s global inclusion strategy focuses on four key areas—workforce, workplace, communities and marketplace (see sidebar to the right). To advance these areas, Baxter has implemented several programs and policies:
Global Inclusion Council
The Global Inclusion Council provides thought leadership, guidance and support to enhance Baxter’s inclusive culture. Composed of leaders from the company’s businesses, regions and functions worldwide, the Council’s charter is to:
- Promote and advocate Baxter’s inclusion philosophy and initiatives;
- Identify issues and barriers in the workplace that could impact an inclusive culture;
- Recommend new ideas or initiatives to accelerate an inclusive culture;
- Identify opportunities to leverage existing initiatives across the company; and
- Ensure inclusion initiatives align to Baxter’s business priorities.
Inclusion and Diversity Training
All employees are required to complete inclusion and diversity online training designed to help employees understand why inclusion and diversity are critical to Baxter’s success. Additionally, all managers are required to complete an inclusion and diversity workshop so each manager plays their part in creating and sustaining an inclusive culture at Baxter.
Fair Opportunity for All Employees
Baxter is committed to fair opportunity for all employees, and recognizes that every individual’s unique background and experiences contribute to a successful organization. Discrimination in hiring, promotion and all other employment decisions on the basis of race, color, religion, gender identity, national origin, age, disability, sexual orientation, veteran status or any other basis protected by federal, state or local laws is prohibited. Baxter’s global operations comply with applicable laws and company business standards around the world. Employees are encouraged to raise any issues or concerns they might have through one of the channels fully outlined in the company’s “Prohibition of Workplace Harassment” policy.
Business Resource Groups
Business Resource Groups (BRGs) support Baxter’s business goals and aim to enhance personal growth and multicultural understanding, while strengthening relationships among employees and with customers and community partners. Baxter has five BRGs: “African-American Leadership Council,” “Asian Leadership Network,” “Baxter Equality Network,” “Building Women Leaders” and “Latinos@Baxter.”
Other Business and Regional Initiatives
- Baxter’s Europe, Middle East and Africa (EMEA) region established the “Female Talent Matters” group.
- Baxter’s BioScience business sponsored “Women in Lifetime Leadership (W.I.L.L.),” a program to support the advancement of women across the business globally. Also, Baxter’s BioScience and Medical Products businesses launched the Women & Ethnic Minority Mentoring program, a diversity-driven mentoring program to accelerate the upward movement of director level and above top talent women and minorities. The program matches mentees with senior leaders from their respective business.
- Baxter’s Asia Pacific region continued its focus on the Building Talent Edge initiative, which aims to create a gender balance in critical leadership positions across 14 countries where Baxter operates in the region. Baxter Japan developed programs focused on mentoring working mothers and launched an alternate work arrangement program designed to promote work/life flexibility.
- Baxter Austria launched an intergenerational inclusion initiative called “Boomers and Millennials,” matching Baxter employees who are recent college graduates with senior, long-term Baxter employees to facilitate exchange and ideas on how the different generations can work better together and learn from each other.
Baxter is committed to the inclusion of diverse businesses (small disadvantaged, minority- and women-owned businesses) in its sourcing and procurement decisions. The company works to develop mutually beneficial relationships with small and diverse suppliers, embracing their importance in many communities. Baxter continues to expand the diversity of its supplier base to reflect the demographics of Baxter’s global customers.
Inclusion and Diversity Awards
- Great Place to Work – Best Multinational Workplaces in Europe
- Great Place to Work in Austria – Great Places to Work Institute
- Great Place to Work in France – Great Places to Work Institute
- Great Place to Work in Ireland – Great Places to Work Institute
- Great Place to Work in Portugal – Great Places to Work Institute
- J-Win Diversity Award – Japan
- Top 50 Employers – Equal Opportunity Magazine
- Employer of Choice for Women citation – Australian government’s Equal Opportunity for Women in the Workplace Agency
In the Community
Baxter also supports and participates in education programs that promote diversity and inclusion in the next generation of young people soon to enter the work force. These include:
- Science@Work, Expanding Minds with Real-World Science, a multi-year commitment to Chicago Public Schools to support teacher training and student development in healthcare and biotechnology
- Instituto Health Sciences Career Academy, a charter school in Chicago consisting predominantly of Latino students, which prepares students for success in healthcare careers; it currently serves more than 200 freshmen and sophomores and will serve 600 students when fully enrolled
- Street Law Inc., a nonprofit organization dedicated to teaching law, democracy and human rights, particularly among groups underrepresented in the legal field.
How nations, companies and individuals respond to global sustainability challenges such as climate change, natural resource scarcity, corruption, unequal access to healthcare and educational opportunities will significantly impact life in the 21st century and beyond. Stakeholders will judge Baxter's performance increasingly by how the company helps to address these global challenges. Baxter's actions demonstrate its leadership, values and commitment.
At Baxter, sustainability means creating lasting social, environmental and economic value by addressing the needs of the company’s wide-ranging stakeholder base. Baxter’s sustainability initiatives support the company’s mission to apply innovative science in the development of medical products and specialty therapies that save and sustain patients' lives.
Sustainability is inherently broad. Baxter's efforts cover a wide range of areas, as reflected by the structure and contents of this report:
- Sustainability at Baxter - Using financial and other resources wisely to benefit company stakeholders and address key sustainability issues;
- Governance, Ethics and Compliance - Operating in a sound and ethical manner and complying with the law wherever Baxter operates; promoting ethical sales and marketing practices globally;
- Employees - Providing a rewarding, inclusive and diverse workplace;
- Environment, Health and Safety - Continually improving the company's environmental performance, generating related financial benefits, and maintaining a safe and healthy workplace;
- Product Responsibility - Ensuring product quality and patient safety, and improving the sustainability performance of Baxter's products and packaging throughout the life cycle;
- Supply Chain - Working with suppliers to improve their social and environmental performance;
- Access to Healthcare - Expanding access to healthcare, including for people at the "base of the pyramid"1 and for those impacted by natural disasters;
- Community Support - Contributing to communities in need worldwide, with a focus on education and the environment; and supporting employee volunteerism and giving;
- Public Policy - Working with lawmakers, governments and policymakers worldwide to improve patient access to critical therapies and address other key issues.
Complementing these activities, Baxter also recognizes the importance of having clear priorities to focus its efforts and direct its initiatives. The company has nine sustainability priorities with corresponding goals for 2015, divided into three broad categories: Our People, Our Operations and Products, and Our World.
Baxter's executive-level Sustainability Steering Committee leads the company's efforts to accelerate and integrate sustainability into its current activities and long-term strategic planning process. The committee's role is to:
- Assess global challenges and opportunities associated with sustainability;
- Increase Baxter's knowledge of sustainability and benchmark other companies that demonstrate leadership and innovation in this area;
- Define, update and oversee Baxter's sustainability strategy;
- Track progress on the company’s sustainability priorities and goals, drive organizational accountability and recognize accomplishments;
- Establish performance objectives, evaluate and address resource needs and help implement sustainability initiatives;
- Provide sustainability progress updates to senior management;
- Identify and determine how to best address emerging issues;
- Guide and inform Baxter's sustainability reporting;
- Solicit stakeholder feedback and review stakeholder inquiries as appropriate; and
- Recommend actions to continually enhance Baxter's sustainability program.
The committee's executive sponsor is Baxter's vice president, Manufacturing. The company's vice president of Environment, Health and Safety serves as committee chair. The committee includes senior representatives from the company's BioScience, Medical Products, Corporate Communications, Ethics and Compliance, Finance, Human Resources, Manufacturing, Research and Development, and Supply Chain organizations.
Committee members sponsor Baxter's sustainability priorities. Each sponsor is accountable for developing goals and achieving progress in his or her respective area, and leads a global, multi-functional team to implement related initiatives. The committee meets quarterly to review progress and to discuss how to address performance gaps. These meetings often feature outside sustainability experts to contribute independent input and perspectives. Additional groups interact and provide input to the committee as needed.
How Sustainability Strengthens Baxter's Business
Baxter’s sustainability initiatives create business value, from attracting and retaining key talent, engaging employees, and reducing operating expense, to ensuring market access, developing new markets, meeting stakeholder expectations, and enhancing Baxter's reputation.
In 2011, 77% of employees worldwide indicated that Baxter's sustainability programs were important to them in the company’s employee engagement survey. The Sustainability Steering Committee uses this data to evaluate how sustainability engages employees and contributes to a satisfying work environment. Baxter will conduct its next employee engagement survey in 2013.
History in Sustainability
Baxter’s commitment to sustainability spans decades. The company established its first formal environmental program and policy in 1977. Since then, milestones have included:
- Establishing The Baxter International Foundation in 1986;
- Taking steps to reduce use of packaging materials, decrease water consumption and waste generation, and conserve energy since 1988;
- Publishing the company’s first formal ethics manual in 1989;
- Introducing Baxter’s first work/life benefit program in 1991;
- Establishing the Corporate Responsibility Office to oversee the company’s ethics and compliance practices in 1993;
- Developing Baxter’s Global Business Practice Standards for Suppliers in 2001;
- Establishing Baxter’s Product Sustainability Review process in 2002; and
- Establishing the company’s Sustainability Steering Committee in 2007.
|1||The term "base of the pyramid" refers to the approximately 4 billion people who each live on less than $1,500 annually and have limited access to the healthcare market.|
- Comp & Benefits
- Work/Life Balance
- Senior Management
- Culture & Values
- Career Opportunities
I have been working at Baxter full-time (more than 5 years)Pros
Lean organization, opportunity to increase breadth of expertiseCons
Commodity vs clinical differentiated portfolio of productsRecommendsNeutral Outlook
Getting an Interview
Getting an Interview
1 person found this helpfulApplication Details
I applied online. The process took 4+ weeks – interviewed at Baxter in March 2015.Interview Details
The interview process took one month from the time of my application to the time of receiving a job offer. Several rounds, starting with the HR person who evaluates your fit for the position, following the phone screen with the hiring manager, F2F interviews with the team members and additional phone interviews. I was interviewed for the Cambridge site, the future Baxalta biopharmaceutical company, and was surprised with high-quality professionalism and expertise of the interviewing team. The atmosphere is pretty casual, but you really need to understand your field.Interview Questions
Accepted OfferPositive ExperienceAverage Interview
- Tell me how would you manage a process/project from scratch? Answer Question